Which has stronger valuation & earnings, SION or IMVT?

Immunovant is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sionna Therapeutics N/A N/A -$75.27M -$2.18 N/A Immunovant N/A N/A -$505.61M -$2.82 N/A

Is SION or IMVT more profitable?

Sionna Therapeutics' return on equity of -32.94% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Sionna Therapeutics N/A -32.94% -31.08% Immunovant N/A -69.59% -62.49%

Does the media prefer SION or IMVT?

In the previous week, Sionna Therapeutics had 10 more articles in the media than Immunovant. MarketBeat recorded 20 mentions for Sionna Therapeutics and 10 mentions for Immunovant. Immunovant's average media sentiment score of 0.27 beat Sionna Therapeutics' score of -0.18 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 1 Very Positive mention(s) 7 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Immunovant 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, PCVX or SION?

Vaxcyte is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxcyte N/A N/A -$766.63M -$7.63 N/A Sionna Therapeutics N/A N/A -$75.27M -$2.18 N/A

Is PCVX or SION more profitable?

Sionna Therapeutics' return on equity of -32.94% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -37.56% -33.62% Sionna Therapeutics N/A -32.94% -31.08%

Does the media refer more to PCVX or SION?

In the previous week, Vaxcyte and Vaxcyte both had 20 articles in the media. Vaxcyte's average media sentiment score of 0.68 beat Sionna Therapeutics' score of -0.18 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 10 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sionna Therapeutics 1 Very Positive mention(s) 7 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RYTM or SION?

In the previous week, Rhythm Pharmaceuticals had 5 more articles in the media than Sionna Therapeutics. MarketBeat recorded 25 mentions for Rhythm Pharmaceuticals and 20 mentions for Sionna Therapeutics. Rhythm Pharmaceuticals' average media sentiment score of 0.47 beat Sionna Therapeutics' score of -0.18 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Sionna Therapeutics 1 Very Positive mention(s) 7 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IBRX or SION?

In the previous week, Sionna Therapeutics had 2 more articles in the media than ImmunityBio. MarketBeat recorded 20 mentions for Sionna Therapeutics and 18 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.35 beat Sionna Therapeutics' score of -0.18 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 4 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Sionna Therapeutics 1 Very Positive mention(s) 7 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, SION or COGT?

Cogent Biosciences is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sionna Therapeutics N/A N/A -$75.27M -$2.18 N/A Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A

Is SION or COGT more profitable?

Sionna Therapeutics' return on equity of -32.94% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Sionna Therapeutics N/A -32.94% -31.08% Cogent Biosciences N/A -104.27% -54.64%

Does the media refer more to SION or COGT?

In the previous week, Sionna Therapeutics had 14 more articles in the media than Cogent Biosciences. MarketBeat recorded 20 mentions for Sionna Therapeutics and 6 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.73 beat Sionna Therapeutics' score of -0.18 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 1 Very Positive mention(s) 7 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Cogent Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive

Sionna Therapeutics (SION) Competitors

$4.66 -46.38 (-90.86%)

As of 03:57 PM Eastern

Compare

SION vs. IMVT, PCVX, RYTM, IBRX, and COGT

Should you buy Sionna Therapeutics stock or one of its competitors? MarketBeat compares Sionna Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sionna Therapeutics include Immunovant (IMVT), Vaxcyte (PCVX), Rhythm Pharmaceuticals (RYTM), ImmunityBio (IBRX), and Cogent Biosciences (COGT).

How does Sionna Therapeutics compare to Immunovant?

Sionna Therapeutics (NASDAQ:SION) and Immunovant (NASDAQ:IMVT) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

Sionna Therapeutics' return on equity of -32.94% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-32.94%	-31.08%
Immunovant	N/A	-69.59%	-62.49%

Sionna Therapeutics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

Sionna Therapeutics presently has a consensus target price of $42.22, indicating a potential upside of 856.34%. Immunovant has a consensus target price of $44.00, indicating a potential upside of 11.03%. Given Sionna Therapeutics' higher probable upside, analysts plainly believe Sionna Therapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	1 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.31
Immunovant	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

47.1% of Immunovant shares are owned by institutional investors. 5.1% of Sionna Therapeutics shares are owned by insiders. Comparatively, 1.9% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Immunovant is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A

In the previous week, Sionna Therapeutics had 10 more articles in the media than Immunovant. MarketBeat recorded 20 mentions for Sionna Therapeutics and 10 mentions for Immunovant. Immunovant's average media sentiment score of 0.27 beat Sionna Therapeutics' score of -0.18 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	1 Very Positive mention(s)	7 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunovant	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sionna Therapeutics beats Immunovant on 10 of the 14 factors compared between the two stocks.

How does Sionna Therapeutics compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Sionna Therapeutics (NASDAQ:SION) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Sionna Therapeutics' return on equity of -32.94% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-37.56%	-33.62%
Sionna Therapeutics	N/A	-32.94%	-31.08%

Vaxcyte presently has a consensus price target of $86.00, suggesting a potential upside of 47.15%. Sionna Therapeutics has a consensus price target of $42.22, suggesting a potential upside of 856.34%. Given Sionna Therapeutics' higher probable upside, analysts clearly believe Sionna Therapeutics is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Sionna Therapeutics	1 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.31

96.8% of Vaxcyte shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by insiders. Comparatively, 5.1% of Sionna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Vaxcyte has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market.

In the previous week, Vaxcyte and Vaxcyte both had 20 articles in the media. Vaxcyte's average media sentiment score of 0.68 beat Sionna Therapeutics' score of -0.18 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	10 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sionna Therapeutics	1 Very Positive mention(s)	7 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vaxcyte is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A

Summary

Sionna Therapeutics beats Vaxcyte on 9 of the 13 factors compared between the two stocks.

How does Sionna Therapeutics compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Sionna Therapeutics (NASDAQ:SION) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

Rhythm Pharmaceuticals currently has a consensus target price of $142.44, indicating a potential upside of 23.16%. Sionna Therapeutics has a consensus target price of $42.22, indicating a potential upside of 856.34%. Given Sionna Therapeutics' higher probable upside, analysts plainly believe Sionna Therapeutics is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Sionna Therapeutics	1 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.31

Sionna Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Sionna Therapeutics' return on equity of -32.94% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Sionna Therapeutics	N/A	-32.94%	-31.08%

Sionna Therapeutics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	41.77	-$196.54M	-$3.11	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A

In the previous week, Rhythm Pharmaceuticals had 5 more articles in the media than Sionna Therapeutics. MarketBeat recorded 25 mentions for Rhythm Pharmaceuticals and 20 mentions for Sionna Therapeutics. Rhythm Pharmaceuticals' average media sentiment score of 0.47 beat Sionna Therapeutics' score of -0.18 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Sionna Therapeutics	1 Very Positive mention(s)	7 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rhythm Pharmaceuticals has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market.

Summary

Sionna Therapeutics beats Rhythm Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Sionna Therapeutics compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Sionna Therapeutics (NASDAQ:SION) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

8.6% of ImmunityBio shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by company insiders. Comparatively, 5.1% of Sionna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Sionna Therapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Sionna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
Sionna Therapeutics	N/A	-32.94%	-31.08%

ImmunityBio has a beta of 0.03, indicating that its stock price is 97% less volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market.

In the previous week, Sionna Therapeutics had 2 more articles in the media than ImmunityBio. MarketBeat recorded 20 mentions for Sionna Therapeutics and 18 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.35 beat Sionna Therapeutics' score of -0.18 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	4 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sionna Therapeutics	1 Very Positive mention(s)	7 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

ImmunityBio currently has a consensus target price of $14.20, suggesting a potential upside of 89.71%. Sionna Therapeutics has a consensus target price of $42.22, suggesting a potential upside of 856.34%. Given Sionna Therapeutics' higher possible upside, analysts plainly believe Sionna Therapeutics is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Sionna Therapeutics	1 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.31

Sionna Therapeutics has lower revenue, but higher earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	70.02	-$351.40M	-$0.97	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A

Summary

ImmunityBio and Sionna Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Sionna Therapeutics compare to Cogent Biosciences?

Sionna Therapeutics (NASDAQ:SION) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Cogent Biosciences is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

Sionna Therapeutics' return on equity of -32.94% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-32.94%	-31.08%
Cogent Biosciences	N/A	-104.27%	-54.64%

Sionna Therapeutics has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

Sionna Therapeutics currently has a consensus price target of $42.22, suggesting a potential upside of 856.34%. Cogent Biosciences has a consensus price target of $45.90, suggesting a potential upside of 11.37%. Given Sionna Therapeutics' higher probable upside, equities analysts clearly believe Sionna Therapeutics is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	1 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.31
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85

In the previous week, Sionna Therapeutics had 14 more articles in the media than Cogent Biosciences. MarketBeat recorded 20 mentions for Sionna Therapeutics and 6 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.73 beat Sionna Therapeutics' score of -0.18 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	1 Very Positive mention(s)	7 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cogent Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Sionna Therapeutics beats Cogent Biosciences on 7 of the 12 factors compared between the two stocks.

Get Sionna Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SION and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SION vs. The Competition

Export

Metric	Sionna Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$200.51M	$3.71B	$7.04B	$12.94B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-2.03	9.08	269.98	24.78
Price / Sales	N/A	1,268.95	651.07	108.19
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	0.64	17.65	11.26	6.43
Net Income	-$75.27M	-$13.25M	$3.45B	$347.27M
7 Day Performance	-91.04%	5.21%	3.50%	2.54%
1 Month Performance	-90.25%	-1.91%	-0.64%	-1.00%
1 Year Performance	-75.01%	60.70%	77.23%	23.33%

Sionna Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SION Sionna Therapeutics	2.9535 of 5 stars	$4.67 -90.9%	$42.22 +805.1%	+188.9%	$210.91M	N/A	N/A	35	Trending News Earnings Report Analyst Forecast Gap Down High Trading Volume
IMVT Immunovant	1.7722 of 5 stars	$39.49 +2.3%	$42.11 +6.6%	+158.4%	$7.97B	N/A	N/A	120	Earnings Report
PCVX Vaxcyte	2.732 of 5 stars	$55.96 +5.6%	$86.00 +53.7%	+94.2%	$7.65B	N/A	N/A	160	Earnings Report Analyst Upgrade
RYTM Rhythm Pharmaceuticals	2.8132 of 5 stars	$105.74 -0.7%	$138.73 +31.2%	+25.7%	$7.30B	$189.76M	N/A	140	Earnings Report Analyst Forecast
IBRX ImmunityBio	2.3804 of 5 stars	$7.45 +9.1%	$14.20 +90.6%	+213.1%	$7.15B	$113.29M	N/A	590	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SION) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sionna Therapeutics (SION) Competitors

SION vs. IMVT, PCVX, RYTM, IBRX, and COGT

How does Sionna Therapeutics compare to Immunovant?

Summary

How does Sionna Therapeutics compare to Vaxcyte?

Summary

How does Sionna Therapeutics compare to Rhythm Pharmaceuticals?

Summary

How does Sionna Therapeutics compare to ImmunityBio?

Summary

How does Sionna Therapeutics compare to Cogent Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SION vs. The Competition

Sionna Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sionna Therapeutics (SION) Competitors

SION vs. IMVT, PCVX, RYTM, IBRX, and COGT

How does Sionna Therapeutics compare to Immunovant?

Is SION or IMVT more profitable?

Which has more risk and volatility, SION or IMVT?

Do analysts recommend SION or IMVT?

Do institutionals & insiders have more ownership in SION or IMVT?

Which has stronger valuation & earnings, SION or IMVT?

Does the media prefer SION or IMVT?

Summary

How does Sionna Therapeutics compare to Vaxcyte?

Is PCVX or SION more profitable?

Do analysts recommend PCVX or SION?

Do institutionals and insiders hold more shares of PCVX or SION?

Which has more volatility & risk, PCVX or SION?

Does the media refer more to PCVX or SION?

Which has stronger earnings & valuation, PCVX or SION?

Summary

How does Sionna Therapeutics compare to Rhythm Pharmaceuticals?

Do analysts rate RYTM or SION?

Is RYTM or SION more profitable?

Which has preferable earnings and valuation, RYTM or SION?

Does the media refer more to RYTM or SION?

Which has more volatility & risk, RYTM or SION?

Summary

How does Sionna Therapeutics compare to ImmunityBio?

Do institutionals and insiders hold more shares of IBRX or SION?

Is IBRX or SION more profitable?

Which has more volatility & risk, IBRX or SION?

Does the media favor IBRX or SION?

Do analysts rate IBRX or SION?

Which has preferable valuation & earnings, IBRX or SION?

Summary

How does Sionna Therapeutics compare to Cogent Biosciences?

Which has higher valuation & earnings, SION or COGT?

Is SION or COGT more profitable?

Which has more volatility & risk, SION or COGT?

Do analysts recommend SION or COGT?

Does the media refer more to SION or COGT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SION vs. The Competition

Sionna Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools